Featured Research

from universities, journals, and other organizations

Targeted therapy boosts lung cancer outcomes

Date:
June 1, 2013
Source:
Dana-Farber Cancer Institute
Summary:
Non-small cell lung cancer patients whose tumor cells had an abnormal ALK gene fared better if treated with crizotinib, a targeted therapy, than with traditional chemotherapy. Median progression-free survival was 7.7 months in the crizotinib group and three months in the chemotherapy group. Patients treated with crizotinib also reported a better quality of life than those treated with standard chemotherapy.

Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene are likely to fare better if treated with a targeted therapy than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.

In a trial involving patients with non-small cell lung cancer (NSCLC) whose tumor cells harbored an abnormal ALK gene, those who received the oral drug crizotinib, which acts directly on ALK, went a median time of 7.7 months before their disease began to worsen, compared to 3 months for patients who received traditional chemotherapy. Patients treated with crizotinib also had a better quality of life than those treated with standard chemotherapy. The findings will be released as an advanced online publication by the New England Journal of Medicine on June 1.

"This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics to target cancer treatments to each patient," says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana-Farber. "ALK now becomes the second abnormal gene that we are able to successfully target in lung cancer with drugs other than chemotherapy." Lung cancers with the first such gene, EGFR, are now commonly treated with EGFR inhibitors before chemotherapy.

The lead author of the study is Alice Shaw, MD, PhD, of Massachusetts General Hospital.

NSCLC is the most common form of lung cancer, striking nearly 200,000 people in the U.S. each year. Although abnormal ALK is found in only about 5 percent of NSCLC cases, that translates into more than 5,000 new patients annually who could potentially benefit from crizotinib therapy, the study authors state.

The phase 3 trial described in the paper involved 347 patients with advanced or metastatic NSCLC who had already been treated with standard chemotherapy. The most common side effects associated with crizotinib therapy -- visual disorders, gastrointestinal problems, elevated liver enzymes, and leg swelling -- were generally mild, Jänne said, and are markedly different than the fatigue and hair loss associated with chemotherapy.

The abnormality in ALK that arises in NSCLC is not, strictly speaking, a mutation (a change in the sequence of DNA within a gene). Rather, it results from a chromosomal rearrangement, in which the structure of a chromosome -- the scaffolding of genetic material -- is altered.

Crizotinib is a drug agent that takes aim at key enzymes within cells called kinases, which are often abnormal in cancer. Originally designed to block a kinase called MET, it was later discovered to target ALK as well. At the time, it wasn't known that ALK was sometimes abnormal in lung cancer. The discovery that it is abnormal in a small percentage of NSCLCs led to its testing against the disease.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. The original article was written by Rob Levy. Note: Materials may be edited for content and length.


Journal Reference:

  1. Alice T. Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J. Solomon, Fiona Blackhall, Yi-Long Wu, Michael Thomas, Kenneth J. O'Byrne, Denis Moro-Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer. New England Journal of Medicine, 2013; 130601060020006 DOI: 10.1056/NEJMoa1214886

Cite This Page:

Dana-Farber Cancer Institute. "Targeted therapy boosts lung cancer outcomes." ScienceDaily. ScienceDaily, 1 June 2013. <www.sciencedaily.com/releases/2013/06/130601133826.htm>.
Dana-Farber Cancer Institute. (2013, June 1). Targeted therapy boosts lung cancer outcomes. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2013/06/130601133826.htm
Dana-Farber Cancer Institute. "Targeted therapy boosts lung cancer outcomes." ScienceDaily. www.sciencedaily.com/releases/2013/06/130601133826.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) — Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) — Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) — A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) — The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins